NASDAQ: RLYB · Life Sciences · 6 alerts · CIK 1739410
Share price
$15.43Close, Nov 16
Market cap
$83M
Shares outstanding
5.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rallybio Corp filings on SEC EDGAR ↗
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
Rallybio Corporation has postponed the closing of its previously announced merger with Avenzo Therapeutics, Inc., which was originally expected to close on November 6, 2026. The delay is due to unsatisfied conditions related to the listing of the company's shares following the transaction. Consequently, the company has also delayed the funding and payment of its previously announced cash distribution to shareholders.
Rallybio Signs $82.7M M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corporation provided a status update on its pending merger with Avenzo Therapeutics, declaring a special cash distribution of approximately $82.7 million ($13.56 per share) to stockholders. The distribution is based on the company's estimated net cash exceeding zero prior to the merger closing and is scheduled for payment on November 13, 2026.